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Insulin resistance, LDL particle size, and LDL susceptibility to
oxidation in pediatric kidney and liver recipients.
Background. Dyslipidemia is common after solid organ trans-
plantation. We have described hypertriglyceridemia in about
50% of our pediatric kidney, and in about 30% of our liver recip-
ients. The aim of the present study was to find out whether this
post-transplantation hypertriglyceridemia after pediatric solid
organ transplantation is associated with insulin resistance and
the occurrence of small, dense low-density lipoprotein (LDL).
Methods. Fifty kidney and 25 liver recipients (aged 4 to
18 years) on triple immunosuppression, and 181 control chil-
dren participated in the study for an average of 5.3 and 6.4 years
after kidney and liver transplantation (range 1 to 11 years),
respectively. Homeostasis model assessments for insulin resis-
tance (HOMA) were calculated and fasting lipoprotein lipid
profile, apolipoprotein A-I and B concentrations, LDL particle
diameter, and indices of LDL susceptibility to copper-induced
oxidation determined.
Results. Kidney patients had significantly higher serum total,
high-density, and low-density lipoprotein cholesterol, triglyc-
eride, apolipoprotein A-I and B concentrations than liver pa-
tients or control subjects (P < 0.003 for all). HOMA indices
higher than the 95th percentile of Canadian normal children
were seen in 50.0% of kidney (of liver 41.2%) recipients
younger than 11 years, and in 27.3% of older recipients (of liver
37.5%). Smaller sized LDL or LDL of increased oxidizability
was not more frequent in patients than in control children.
Conclusion. Pediatric kidney recipients had significantly
higher lipid and insulin concentrations than healthy control
children. Combined hyperlipidemia and features of the dys-
metabolic syndrome were common in children after kidney and
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liver transplantation. However, no small, dense LDL, or LDL
prone to oxidation was seen in either group.
Atherosclerosis is the most important cause of death
and late graft loss after kidney transplantation (KTx)
[1]. Adult liver recipients have a 2.5-fold relative risk
for ischemic cardiovascular events, and a 3-fold risk for
death [2]. Dyslipidemia is frequent after transplanta-
tion (Tx), affecting up to 70% of kidney [3] and 50%
of liver recipients [4]. High triglyceride (TG) and low
high-density lipoprotein cholesterol (HDL-C) concen-
trations, predominance of small low-density lipoprotein
(LDL) particles, and elevated insulin and glucose con-
centrations characterize insulin resistance syndrome [5].
When combined with abdominal obesity, impaired glu-
cose tolerance, or type 2 diabetes mellitus and hyper-
tension, they form a cluster of risk factors with high
atherogenic potential [6]. Increased prevalence of insulin
resistance [7, 8] and dysmetabolic syndrome has been de-
scribed in adult KTx patients [9]. After a liver transplan-
tation (LTx) due to cirrhosis, increased first-phase insulin
secretion in response to high glucose levels persisted de-
spite LTx normalized pre-Tx insulin resistance [10]. In
a large meta-analysis, new onset insulin-dependent di-
abetes was reported in 13.4% of patients on calcineurin
inhibitors (cyclosporine and tacrolimus) after solid organ
transplantation [11].
Elevated LDL cholesterol (LDL-C) concentration and
small, dense LDL particles prone to oxidation promote
atherosclerosis [12–14]. Variation in TG concentration
predicted 62% of LDL diameter variation in healthy
adults [15]. In addition to environmental factors, the
diameter of LDL is genetically determined [16]. Lag
time before oxidative modification of LDL in vitro is
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thought to reflect the total antioxidant status of LDL
[17]. HDL provides multiple mechanisms in protection
against atherosclerosis (e.g., through reverse cholesterol
transport and the ability of HDL to decrease the peroxi-
dation of LDL [18]).
We have reported elevated TG concentrations in 50%
and 30% of pediatric kidney and liver recipients on sim-
ilar triple immunosuppression, respectively, without in-
creased frequency of low HDL-C concentrations. Half
of the kidney recipients but only one sixth of the liver
recipients and control subjects had elevated total choles-
terol (TC) concentration (>5.0 mmol/L). Kidney graft
and pretransplantation TC concentration, independent
of glomerular filtration rate (GFR) and proteinuria, were
risk factors for this hypercholesterolemia [18]. In the kid-
ney recipients, obesity, a high dose of MP, and protein-
uria were significant risk factors for dyslipidemia [18].
These findings raised hypotheses that (1) children with
solid organ transplantation have increased prevalence of
small, dense, and easily oxidative LDL, and hyperinsu-
linemia, (2) size and oxidizability of LDL are associated
with lipoprotein, apolipoprotein B, and insulin concen-
trations, as well as apolipoprotein E phenotype, (3) the
prevalence of small, dense LDL is higher in kidney than
in liver recipients.
METHODS
Patients
Patients. Fifty children in the KTx group and 25 chil-
dren in the LTx group with acceptably functioning grafts
took part in a cross-sectional study between September
1997 and April 1999. The inclusion criteria were: age be-
tween 3 and 17 years, follow-up time at least 1 year af-
ter Tx and glomerular filtration rate (GFR) >40 mL/min/
1.73m2. Mean follow-up time after Tx was 5.3 years (range
1–11 years) and 6.4 (range 1–11 years) in the KTx and LTx
groups, respectively. The participation rate was 88.0% in
the KTx and 92.6% in the LTx group. Pre-Tx diagnoses in
the KTx group were the following: congenital nephrosis
(N = 31), urethral valve (N = 5), nephronophthisis (N =
2), polycystic kidney disease (N = 3), glomerulonephritis
(N = 2), prune-belly syndrome (N = 1), Alport’s syn-
drome (N = 1), mega-ureter (N = 1), dysplastic kidney
(N = 1), bilateral multicystic kidneys (N = 1), Denys-
Drash syndrome (N = 1), and renal insufficiency due to
a complication of prematurity (N = 1). Pre-Tx diagnoses
in the liver group were: tyrosinemia (N = 7), hepatitis
(N = 1), biliary atresia (N = 9), hepatoblastoma (N = 4),
hepatocellular carcinoma (N = 1), homozygous familial
hypercholesterolemia (N = 1), Wilson’s disease (N = 1),
and a-1-antitrypsin deficiency (N = 1). None of the pa-
tients were hypothyroid, and all were on their usual diet.
If there was marked weight gain after Tx, energy restric-
tion and a diet low in saturated fatty acids was advised.
The control group consisted of 181 (112 boys and 69 girls)
children without regular medication, acute infection, or
inflammatory or metabolic disease [19].
Medication. The immunosuppressive protocols have
been described [19]; they included triple therapy with
cyclosporine A (CsA) in microemulsion composition,
methylprednisolone (MP) given on alternate days, and
azathioprine (AZA). Two boys were on triple therapy
with tacrolimus instead of CsA in both the KTx and LTx
groups. In the LTx group, one girl was on tacrolimus and
MP.
Ethics. Parents and children gave written informed
consent. The ethical Committees of Tampere and
Helsinki University Hospital approved the study.
Methods
Collection of clinical data (kidney function as GFR,
creatinine, and diurnal urinary protein; liver function as
serum alanine aminotransferase, albumin, total bilirubin,
and thromboplastin time; pubertal stage according to
Tanner’s classification), anthropometric measurements,
blood sampling, and analyses were done as described [20].
In short, we expressed measured height and body mass in-
dex (BMI) calculated from measured height and weight,
as standard deviation score (SDS) calculated according
to the equation: (observation — mean observation for
age)/SD. SD represents the standard deviation for the
normal Finnish population of the same numeric age and
gender [21, 22]. We measured blood pressure from the
right upper arm of the sitting patient with an electronic
sphygmomanometer, and used the mean of the 3 mea-
surements in the analysis.
Lipid and apolipoprotein assays. Blood samples for
lipid, cyclosporine trough concentration, insulin, and glu-
cose analyses were taken after a 12-hour overnight fast.
Serum and plasma for lipid analyses were immediately
separated by centrifugation and stored at −70◦C. The
serum TG, TC, and HDL-C concentrations, as well as
apolipoprotein B (apoB) and A-I (apoA-I) concentra-
tions, were analyzed using Cobas Integra 700 automatic
analyzer with reagents and calibrators as recommended
by the manufacturer (Roche Diagnostics, Basel, Switzer-
land). We calculated LDL-C concentration by Friede-
wald’s formula [23]. Serum TG did not exceed 4.0 mmol/L
in any of the subjects studied. Lp (a) was determined by
a radioimmunologic method and expressed in units per
liter (U/L; 1 mg/L = 0.7 U/L). Sensitivity of the assay
was 17 U/L. Concentrations >651 U/L (95th percentile
of our control children) were considered to be elevated.
ApoE phenotype was determined from Tx patients by
isoelectric focusing and immunoblotting [20].
Glucose and insulin assays. Blood glucose was
analyzed by enzymatic and serum insulin by radioim-
munologic methods. We estimated insulin resistance by
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homeostasis model assessment [insulin resistance = fast-
ing insulin/(22.5e−ln fasting glucose)] [24]. The HOMA index
is based on the assumption that normal adults have a
HOMA index of 1. We compared the HOMA indices of
9- and 13-year-old Canadian healthy children [25] to our
patients divided into subgroups according to gender and
age [the median between the 2 cohorts of 9- and 13-year-
old Canadians (i.e., <11 years vs. older)]. Oral glucose
tolerance tests (OGTT) were performed after a 12-hour
fast, and an oral dose of glucose 1.75 g/kg (maximum
75 g) was given. Samples for blood glucose and serum
insulin measurements were collected at 0, 30, 60, 90, 120,
and 180 minutes. Criteria for hyperinsulinemia were diag-
nosed as serum fasting insulin exceeding 20 mU/L and/or
a peak insulin concentration exceeding 150 mU/L [26].
Impaired glucose tolerance was determined according to
WHO criteria: blood glucose 5.6 to 6.0 mmol/L after an
overnight fast or 6.7 to 9.9 mmol/L at 120 minutes in the
OGTT.
LDL characteristics. The estimation of LDL particle
size from EDTA plasma samples was done by nondena-
turing gradient gel electrophoresis. In vitro oxidation of
LDL was done by copper-induced oxidation of LDL [20].
The maximal storage times for in vitro oxidation of LDL
and LDL particle size were 30 and 45 months, respec-
tively.
Food records. Forty-seven of the kidney and 24 of the
liver patients completed a 6-day food record, which in-
cluded 2 weekend days. The patients or their parents were
asked to record the type and quantity of the all foods and
drinks consumed. The record was checked in an interview
with the patient or parent by one of the authors (A.S.).
Complementary data from another parent or caretaker
were in some cases elicited by telephone (e.g., in cases
when the type of fat used in preparing the dish was not
reported). Data on day-care meals and school lunches
were checked by telephone from the kitchen personnel of
the day-care centers and schools. Simple models of foods
(e.g., different-sized potatoes), volume, and household
measures and pictures of food amounts and pictures of
dietary fat packages on the market at the time were used
in checking the food record data. Of the controls, 178
completed a 3-day food record, which included 1 week-
end day. Food record data were analyzed with a Finnish
nutrient software program (Nutrica 3.1 Fin, The Social
Insurance Institution of Finland, Turku, Finland).
Statistical analysis
Normality of distributions was tested by one-sample
Kolmogorov-Smirnov goodness of fit test. If the distri-
bution was skewed, we used a logarithmic scale in ap-
propriate cases, but described the data as untransformed
values. When the distribution of TG was skewed, we dis-
played the mean of TG distribution as a geometric mean
(the antilogarithm of the mean of the log transformed
distribution). We presented normally distributed contin-
uous variables as mean, range, and confidence intervals,
and discrete or skewed distributed variables as median,
lower (Q1), and upper quartile (Q3). We presented MP
dose as daily dose, which equals the dose on alternate
days divided by 2. We tested differences in means be-
tween groups with t test or analysis of variance (ANOVA,
Bonferroni correction for multiple comparisons) for nor-
mally distributed continuous variables, or Mann-Whitney
or Kruskal-Wallis test for skewed or discrete variables.
The significance of difference in the frequency distribu-
tion was tested by chi-square test. In cases where the
frequencies in the cells were low, Fisher exact test was
used instead. We calculated Pearson correlation coeffi-
cients for normally distributed variables and Spearman
correlation coefficients for variables of skewed or dis-
crete distributions. We presented a maximum of 4 most
significant univariate correlation coefficients. In the ta-
bles, we tested all differences between the groups and
presented those that were statistically significant. We con-
sidered two-sided P values less than to be 0.05 statistically
significant.
We evaluated the determinants of TG concentration,
LDL susceptibility to in vitro oxidation (lag time and ox-
idation rate) and LDL particle size by multivariate linear
regression analysis, and used forward stepwise method.
Normally distributed variables were included as contin-
uous, and variables of skewed or discrete distributions
as dichotomized. We did analyses separately for both Tx
groups. We included a maximum of 7 possible risk fac-
tors first in 4 different blocks (Table 1). In all first blocks
for LDL characteristics, HDL-C and TG concentrations
were included. Similarly, in all first blocks for TG, HDL-C
concentration and HOMA index were included. Signifi-
cant variables from the first blocks were then included in
the final block. The variables in the model did not show
a strong correlation (r < 0.4). A variable was included
in the multivariate model if its significance was < 0.05,
and removed if the significance was > 0.1. Computations
were carried out using SPSS for Windows version 10.1
(SPSS, Inc., Chicago, IL, USA).
RESULTS
The patient and control groups were similar in age, rel-
ative weight, and distributions of pubertal stage (Table 2).
The kidney recipients had higher systolic blood pressure
than the controls (P < 0.001). There were differences in
the intake of carbohydrates between the groups; 41.7%
(N = 10) of the liver recipients reported high carbo-
hydrate intake (>55% of energy) compared to 10.6%
(N = 5) of the kidney recipients, and 22.5% (N = 40)
of the controls (P = 0.011) (Table 2). Medications are
given in Table 3. The kidney function of kidney recipi-
ents was inferior to that of liver recipients (GFR: P <
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Table 1. Block division of multivariate linear regression models for triglyceride, LDL particle size, and variables of LDL oxidation
Characteristics of patients
Gender (0 = boy, 1 = girl)
Time since transplantation years
Body mass index standard deviation score
Pubertal stage (0 = prepubertal, 1 = pubertal or postpubertal)
Indication for transplantation (kidney: 0 = NPHS1 vs. 1 = other; liver: 0 = liver failure vs. 1 = other)
HDL-C mmol/L
Triglyceride mmol/L (logarithmic scale, in the model for triglyceride HOMA included)
Medication and blood pressure
Blood cyclosporine trough level lmol/L
Methylprednisolone dose (0 = two lowest tertiles, 1 = the highest tertile)
Use of growth hormone (0 = no, 1 = yes)
Use of antihypertensives (in the model for kidney recipients only; 0 = no, 1 = yes)
Systolic blood pressure mm Hg
HDL-C mmol/L
Triglyceride mmol/L (logarithmic scale, in the model for triglyceride HOMA included)
Kidney and liver function
Graft (in the model for kidney recipients only, 0 = cadaver, 1 = living related donor)
Glomerular filtration rate [0 = two highest tertiles, 1 = the lowest tertile (in the kidney group <48.6 mL/min/1.73m2,
in the liver group <65.4 mL/min/1.73m2)]
Thromboplastin time (0 = two highest tertiles, 1 = the lowest tertile)
Urinary protein (in the model for kidney recipients only; 0 = “≤200 mg/day,” 1 = “>200 mg/day”)
HDL-C mmol/L
Triglyceride mmol/L (logarithmic scale, in the model for triglyceride HOMA included)
Lipids, insulin resistance, and diet
Low-density lipoprotein particle size (not included the model for triglyceride)
Homeostasis model assessment index for insulin resistance [24] (0 = two lowest tertiles, 1 = the highest tertile)
Apolipoprotein E phenotype (E3/E4 or E4/E4, 0 = no, 1 = yes)
Intake of carbohydrate (percentage of total energy; 0 = “<55 E%,” 1 = “≥55 E%”)
Intake of saturated fat (percentage of total energy)
HDL-C mmol/L
Triglyceride mmol/L (logarithmic scale, in the model for triglyceride HOMA included)
Abbreviations are: NPHS1, congenital nephrotic syndrome; HDL-C, serum high-density lipoprotein cholesterol concentration. Dependent variables were not
included in the model as independent variables.
Table 2. Clinical characteristics of 75 kidney or liver transplant recipient children and 181 controls
Kidney Liver Control
(N = 50) (N = 25) (N = 181)
Gender, Male/Female, N 33/17 15/10 112/69
Age years [median (range)] 10.8 (4.3–17.2) 9.3 (3.9–17.9) 9.1 (3.2–18.7)
Median age at Tx years [median (range)] 3.2 (1.1–15.3)a 2.0 (0.4–16.3)
Height SDS, mean (CI) −1.3 (−1.6; −1.0)b −1.7 (−2.1; −1.3) 0.2 (0.0; 0.3)
BMI SDS, mean (CI) 0.3 (−0.1; 0.6) 0.5 (−0.1; 1.1) 0.3 (0.1; 0.5)
Pubertal stage (Tanner’s classification)
Pre-pubertal% (N) 48.0 (24) 60.0 (15) 61.8 (112)
Pubertal% (N) 42.0 (21) 32.0 (8) 29.8 (54)
Post-pubertal% (N) 10.0 (5) 8.0 (2) 8.3 (15)
Systolic blood pressure, mmHg, mean (CI) 119 (115; 122)c 115 (109; 120) 109 (107; 110)
Diastolic blood pressure, mmHg, mean (CI) 65 (61; 68) 69 (69; 74) 65 (63; 66)
Diet (N = 47/24/178)
Energy intake, kJ, median (Q1; Q3) 7.2 (5.6; 8.8) 7.0 (6.1; 7.6) 7.5 (6.4; 8.8)
Carbohydrates, E%, mean (CI) 49.0 (47.6; 50.5)d 53.2 (51.0; 55.4) 50.7 (49.8; 51.5)
Fat, E%, mean (CI) 34.1 (32.8; 35.4) 31.2 (29.1; 33.3) 33.2 (32.5; 33.9)
Saturated fat, E%, mean (CI) 14.5 (13.8; 15.2) 13.2 (11.8; 14.6) 14.1 (13.7; 14.5)
Dietary cholesterol, mg, median (Q1; Q3) 195 (157; 261) 207 (157; 254) 221 (174; 278)
a P = 0.014
b P < 0.001; kidney group vs. controls and liver group vs. controls, P < 0.001
c P < 0.001; kidney group vs. controls, P < 0.001 (liver group vs. controls, P = 0.074)
d P = 0.012; kidney vs. liver P = 0.01
STATISTICS: chi square test, Kruskal-Wallis test, ANOVA (Bonferroni correction for multiple comparisons), E% = percent of energy.
NOTES: Part of the control data has been published [19, 20].
0.001; creatinine: P < 0.001) (Table 4). Liver recipients
had higher serum alanine aminotransferase concentra-
tion (P < 0.001) and lower serum thromboplastin time
(P = 0.019) than kidney recipients. Kidney recipients had
higher serum TC (P < 0.001) and LDL-C concentrations
(P = 0.002), and also higher HDL-C (P < 0.001) and
apoA-I concentrations (P = 0.001), than liver recipients
or controls (Table 5).
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Table 3. Medication of 75 kidney or liver transplant recipient children
Kidney Liver
(N = 50) (N = 25)
Cyclosporine A mg/kg/day,
median (Q1; Q3)
5.4 (3.7; 6.8) 4.6 (3.6; 5.3)
Blood cyclosporine trough
concentration lg/L, median
(Q1; Q3)
94 (78; 119) 102 (73; 134)
Methylprednisolone mg/kg/day,
median (Q1; Q3)
0.09 (0.07; 0.12)a 0.07 (0.06; 0.10)
Azathioprine mg/kg/day, median
(Q1; Q3)
1.3 (1.2; 1.4)b 1.2 (1.1; 1.3)
Antihypertensives % (N) 28.0 (14)c 8.0 (2)
b-blockers or diuretics % (N) 6.0 (3) 4.0 (1)
Growth hormone treatment %
(N)
16.0 (8) 24.0 (6)
Hydrocortisone substitution %
(N)
20.0 (10) 40.0 (10)
Q1, lower quartile; Q3, upper quartile. Mann-Whitney test and chi-square test
were used.
a P = 0.014.
bP = 0.001.
cP = 0.046.
Insulin, glucose, and TG
An increased TG concentration (>1.5 mmol/L) was
seen in 40.0% (N = 20) of the KTx, in 16.0% (N = 4) of
the LTx patients, and in 7.2% (N = 13) of controls (P <
0.001). Hyperinsulinemia, according to either high fasting
or peak insulin concentration >150 mU/L during OGTT,
was seen in 10.0% (N = 5) of the kidney and in 16.0%
(N = 4) of the liver recipients (Table 6). In the KTx group,
HOMA indices higher than the 95th percentile of Cana-
dian normal population were observed in 50.0% (N = 14)
of the younger, and in 27.3% (N = 6) of older children,
respectively, indicating a high prevalence of insulin resis-
tance. In the LTx group, the corresponding figures were
41.2% (N = 7) and 37.5% (N = 3). Both an increased TG
concentration and a high HOMA were present in 22.0%
(N = 11) of KTx and 4.0% (N = 1) of LTx patients. Im-
paired glucose tolerance was seen in 20.0% (N = 10)
and 32.0% (N = 8) of patients in KTx and LTx groups,
respectively. One girl in the LTx group was classified as
prediabetic with blood glucose of 10.4 mmol/L at 2 hours.
In KTx patients, TG concentration correlated with HDL-
C (r = −0.381, P = 0.006) and BMI SDS (r = 0.369, P =
0.008), while no such correlations were seen in the LTx
group. In both Tx groups, fasting insulin correlated with
systolic blood pressure (kidney: r = 0.379, P = 0.007; liver:
r = 0.565, P = 0.003). In the final multivariate regression
model, variation in HDL-C, BMI SDS, and urinary pro-
tein explained 30.8% of variation in TG in the KTx group
(Table 7).
LDL particle size
KTx patients had larger LDL particle size than controls
(P < 0.001) (Table 5).
In the KTx group, variation in HDL-C concentra-
tion explained 40.7% of variation in LDL particle size,
Table 4. Graft function in 75 kidney or liver transplant recipient
children studied for dyslipidemia
Kidney Liver
(N = 50) (N = 25)
GFR mL/min/1.73m2, mean (CI) 60 (56; 65)a 84 (71; 96)
(range) (41–106) (41–165)
Creatinine lmol/L, median (Q1; Q3) 96 (80; 109)a 58 (48; 75)
Alanine aminotransferase U/L, median
(Q1; Q3)
13 (12; 19)a 32 (14; 61)
Albumin g/L, mean (range) 37 (24–45)b 39 (31–45)
Total bilirubin lmol/L, median (Q1; Q3) ND 10 (7; 15)
Thromboplastin time%, mean (CI) 102 (95; 109)c 88 (80; 96)
ND, not determined; Q1, lower quartile; Q3, upper quartile. t test and
Mann-Whitney test were used.
aP <0.001.
bSerum albumin concentration of 9 kidney patients.
cP = 0.019.
whereas that in TG concentration explained 12.8%
(Table 8). In the LTx and control groups, variation in
HDL-C concentration explained 36.1% and 17.9% of
variation in LDL diameter, respectively. Univariate cor-
relation was seen between LDL particle size and HOMA
index for insulin resistance (r = 0.321, P = 0.023) in the
KTx group, and in the LTx group between LDL particle
size and BMI SDS (r = 0.510, P = 0.011). In the final
multivariate regression model, variation in HDL-C con-
centration and pubertal stage explained 46.5% of varia-
tion in the LDL particle size in the KTx group (Table 7),
and variation in HDL-C concentration and BMI SDS ex-
plained 59.8% of variation in the LDL particle size in the
LTx group.
LDL susceptibility to oxidation
LDL oxidation rate and maximum amount of formed
dienes were highest in the KTx group and lowest in the
LTx group (P = 0.001, Table 5). In kidney patients, lag
time correlated positively with HDL-C (r = 0.290, P =
0.05), and negatively in the liver patients (r = −0.539, P =
0.005) (Table 8). In the liver group, oxidation rate corre-
lated with TC concentration (r = 0.724, P < 0.001). Oxi-
dation rate was also associated with maximum amount of
dienes formed in both groups (kidney group: r = 0.748,
P < 0.001; liver group: r = 0.864, P < 0.001).
DISCUSSION
Risk for cardiovascular diseases is significantly ele-
vated in kidney and liver recipients [1, 2]. This risk is a
combination of preexisting factors, such as the underlying
kidney disease leading to specific metabolic abnormali-
ties and transplantation, and the factors associated with
transplantation, especially graft function and immuno-
suppressive therapy [1, 27]. In our study, kidney trans-
plant recipients had significantly higher TC, LDL-C, and
apoB concentrations than liver recipients and controls.
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Table 5. Serum lipids and lipoproteins and characteristics of LDL particles in 50 kidney and 25 liver transplant recipient children and 181 controls
Kidney Liver Control
(N = 50) (N = 25) (N = 181) P value
Lipoprotein values
TC mmol/L, mean (CI) 4.99 (4.71; 5.28) 4.25 (3.83; 4.68) 4.18 (4.07; 4.29) <0.001a,b
LDL-C mmol/L, mean (CI) 2.70 (2.48; 2.92) 2.16 (1.84; 2.48) 2.39 (2.30; 2.48) 0.002a,b
HDL-C mmol/L, mean (CI) 1.62 (1.52; 1.72) 1.56 (1.37; 1.74) 1.42 (1.38; 1.47) <0.001a
TG mmol/L, geometric mean (CI) 1.34 (1.17; 1.52) 1.09 (0.93; 1.28) 0.72 (0.67; 0.77) <0.001a,c
HDL-C/TC%, mean (CI) 33.2 (31.1; 35.2) 36.8 (33.4; 40.2) 34.6 (33.5; 35.7) NS
ApoA-I g/L, mean (CI) 1.53 (1.45; 1.60) 1.46 (1.34; 1.59) 1.39 (1.35; 1.42) 0.001a
ApoB g/L, mean (CI) 0.83 (0.77; 0.89) 0.70 (0.62; 0.77) 0.73 (0.71; 0.76) 0.001a,b
Lp (a) U/L, median (Q1; Q3) 65 (21; 143) 67 (32; 161) 85 (27; 238) NS
(range) (<17; 673) (<17; 535) (<17; 1157)
Apolipoprotein E3/E4 or E4/E4 phenotype% (N) 28.0 (14) 24.0 (6) ND NS
LDL characteristics
Diameter of LDL nm, mean (CI)d 26.9 (26.8; 27.1) 26.8 (26.6; 26.9) 26.6 (26.5; 26.7) <0.001a
Diameter of LDL <25.6 nm% (N) 2.0 (1) 0.0 (0) 1.1 (1) <0.001
Diameter of LDL 25.6<×<26.5 nm,% (N) 18.0 (9) 16.7 (4) 49.5 (47)
Diameter of LDL 26.5<×<27.2 nm,% (N) 42.0 (21) 70.8 (17) 38.9 (37)
Diameter of LDL>27.2 nm,% (N) 38.0 (19) 12.5 (3) 10.5 (10)
Lag time minutes, mean (CI)e 78 (76; 81) 76 (71; 80) 77 (75; 78) NS
Oxidation rate lmol/min, mean (CI)e 0.44 (0.43; 0.45) 0.40 (0.37; 0.43) 0.43 (0.42; 0.44) 0.001b,c
Maximum amount of dienes formed nmol/mg, mean (CI)e 568 (553; 584) 522 (496; 549) 547 (538; 556) 0.001a,b
Abbreviations: TC, serum total cholesterol concentration; CI, 95% confidence interval for mean; LDL-C, serum low density lipoprotein concentration; HDL-C,
serum high-density lipoprotein cholesterol concentration; TG, serum triglyceride concentration; ApoA-I, serum apolipoprotein A-I concentration; ApoB, serum
apolipoprotein B concentration; Lp (a), serum lipoprotein (a) concentration; NS, not significant; Q1, lower quartile, Q3, upper quartile; LDL, low density lipoprotein;
ND, not determined. ANOVA (Bonferroni correction for multiple comparisons), Kruskal-Wallis test, and chi-square test were used. Part of the control data has been
published [19, 20].
aKidney group vs. controls, P < 0.05.
bKidney vs. liver group, P < 0.05.
cLiver group vs. controls, P < 0.05.
dLDL particle size was analyzed for 24 children in the liver recipient, and for 95 children in the control group.
eLDL susceptibility to in vitro oxidation was analyzed for 46 children in the kidney recipient, and for 88 children in the control group.
Table 6. Serum insulin and homeostasis model assessment index for insulin resistance in 50 kidney and 25 liver transplanted children and
181 controls
Kidney Liver Control
(N = 50) (N = 25) (N = 181) P value
Insulin
Insulin mU/L, median (Q1; Q3) 10 (7; 16) 9 (5; 15) 5 (3; 7) <0.001
Prepubertal, median (Q1; Q3) (N = 24/15/112) 8 (4; 11) 6 (4; 11) 4 (3; 5) <0.001
Pubertal, median (Q1; Q3) (N = 21/8/54) 14 (10; 19) 13 (5; 36) 7 (5; 10) <0.001
Postpubertal, median (Q1; Q3) (N = 5/2/15) 9 (8; 14) (9; 18) 6 (5; 14) NS
Frequency of high fasting insulin% (N) 10.0 (5) 12.0 (3) 1.7 (3) NS
Frequency of hyperinsulinemia during OGTT% (N) 3.9 (2) 8.0 (2) NS
Insulin resistance
HOMA insulin resistance, median (Q1; Q3) 2.2 (1.4; 3.3) 1.8 (0.9; 2.9) NS
Prepubertal, median (Q1; Q3) (N = 24/15) 1.6 (0.8; 2.4) 1.2 (0.9; 2.2) NS
Pubertal, median (Q1; Q3) (N = 21/8) 2.9 (2.2; 4.4) 2.9 (2.0; 7.0) NS
Postpubertal, median (Q1; Q3) (N = 5/2) 1.7 (1.6; 2.9) 2.7 (1.7; 3.7) NS
Abbreviations: Q1, lower quartile; Q3, upper quartile; NS, not significant; OGTT, oral glucose tolerance test; HOMA, insulin resistance index according to
homeostasis model assessment [24]. Kruskal-Wallis test and chi-square test were used. Part of the control data has been published [19, 20].
Both kidney and liver recipients had higher serum triglyc-
eride concentrations than the controls. Despite this dys-
lipidemia, small, dense, and easily oxidative LDL was not
seen in either the kidney or in the liver Tx group. Signs
of dysmetabolic syndrome were seen in both solid organ
recipient groups because a high HOMA index, indicat-
ing insulin resistance, was found in 50.0% of the young
kidney recipients (<11 years of age) and in 41.2% of the
liver recipients. Impaired glucose tolerance was found in
20.0% and 32.0% of kidney and liver recipients, respec-
tively.
Hyperlipidemia, hypertension, dysmetabolic syn-
drome, and new-onset insulin dependent diabetes are
well-known risk factors for cardiovascular diseases af-
ter transplantation, but also risk factors for graft failure
because they may promote vascular changes in trans-
planted organs and, thereby, enhance the development
of chronic rejection [1, 9, 28, 29]. Insulin-resistant indi-
viduals usually have an elevated concentration of TG, a
decreased concentration of HDL-C, and preponderance
of small, dense LDL [30]. Forty percent of the kidney re-
cipients had an elevated TG concentration. As expected,
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Table 7. Multivariate linear regression models for 50 kidney and 25 liver transplant recipients
First blocks Final blockDependent Independent
Organ group variable Block variable B Std. error P R2 B Std. error P R2
Kidney TG A HDL-Ca −0.44 0.18 0.019 0.234 −0.45 0.17 0.013 0.308
BMI SDS 0.11 0.05 0.024 0.11 0.05 0.031
C HDL-C −0.53 0.17 0.004 0.246
Urinary protein 0.56 0.24 0.026 0.53 0.24 0.031
LDL particle size A HDL-Ca 1.07 0.17 <0.001 0.465 1.07 0.17 <0.001 0.465
Pubertal stage 0.26 0.11 0.028 0.26 0.11 0.028
Lag time for LDL B HDL-Cb 8.57 3.35 0.014 0.210 7.15 3.32 0.037 0.179
oxidation
(N = 46) Use of growth hormone 6.33 2.92 0.036 6.66 2.98 0.031
Liver LDL particle size A HDL-Ca 0.48 0.11 <0.001 0.598 0.48 0.11 <0.001 0.598
(N = 24) BMI SDS 0.13 0.04 0.002 0.13 0.04 0.002
Lag time for LDL A HDL-Cc −16.93 3.72 <0.001 0.542 −7.53 3.42 0.038 0.590
oxidation
Time since transplantation 1.96 0.63 0.005
Indication for LTx: 8.19 3.88 0.047
failure vs. other
B Use of growth hormone 13.60 3.93 0.002 0.363 14.24 3.56 0.001
Oxidation rate B Methylprednisolone dose −0.06 0.02 0.018 0.441
HDL-Ca 0.06 0.02 0.023 0.08 0.03 0.005 0.302
D HDL-C 0.09 0.02 0.001 0.462
Intake of saturated fat −0.01 0.003 0.037
Abbreviations: B, beta (i.e., the unstandardized coefficients of the estimated regression model); std. error, standard error of the unstandardized coefficients of the
estimated regression model; P, P value of the significance; R2, the proportion of variation in the dependent variable explained by the regression model; TG, serum
triglyceride concentration; HDL-C, serum high-density lipoprotein cholesterol concentration; BMI SDS, body mass index standard deviation score, LDL, low-density
lipoprotein; LTx, liver transplantation. Linear regression was performed. The setting and block division of variables are presented in Table 1.
a HDL-C was significant in all first blocks. Blocks with HDL-C as the only significant variable are not presented.
b HDL-C was also significant in block D.
c HDL-C was also significant in blocks C and D.
Table 8. Univariate linear regression models for characteristics of LDL with lipids, lipoproteins and apolipoproteins as independent variables in
kidney and liver transplantation groups and controls
Kidney transplant group Liver transplant group Control groupIndependent
Dependent variable variable B Std. error P R2 B Std. error P R2 B Std. error P R2
LDL particle size HDL-C mmol/L 1.01 0.18 <0.001 0.407 0.50 0.14 0.002 0.361 0.66 0.15 <0.001 0.179
(N = 50/24/95)
TG mmol/L −0.41 0.16 0.011 0.128 −0.29 0.10 0.006 0.077
ApoA-I g/L 1.02 0.28 0.001 0.223 0.62 0.22 0.010 0.263 0.61 0.21 0.005 0.082
ApoB g/L −0.77 0.38 0.047 0.081 −0.63 0.28 0.030 0.050
Lag time for LDL TC mmol/L −5.28 1.85 0.009 0.261
oxidation
(N = 46/25/88) LDL-C mmol/L −6.29 2.55 0.021 0.210
HDL-C mmol/L 6.99 3.47 0.050 0.084 −12.54 4.09 0.005 0.291
TG mmol/L
ApoA-I g/L 9.84 4.74 0.044 0.091 −14.82 6.39 0.030 0.189
ApoB g/L −26.14 11.04 0.027 0.196
Abbreviations: B, beta (i.e., the unstandardized coefficients of the estimated regression model); std. error, standard error of the unstandardized coefficients of
the estimated regression model; P, P value of the significance; R2, the proportion of variation in the dependent variable explained by the regression model; LDL,
low density lipoprotein; HDL-C, serum high-density lipoprotein cholesterol concentration; TG, serum triglyceride concentration; ApoA-I, serum apolipoprotein A-I
concentration; ApoB, serum apolipoprotein B concentration; TC, serum total cholesterol concentration. Linear regression was performed.
variation in TG concentration showed an association with
variation in HDL-C concentration, obesity, and protein-
uria, and also a univariate association with LDL diam-
eter. Thus, the lipid associations typical of dysmetabolic
syndrome were seen in our kidney recipients. The under-
lying causes of hypertriglyceridemia can be treated, at
least to some extent, by adequate weight control and by
minimizing factors leading to proteinuria.
Corticosteroids are associated with combined hyper-
lipidemia, hyperinsulinemia, and hypertension in non-
transplant patients [31] and transplant recipients [32].
Lemieux et al showed that kidney recipients on pred-
nisone had higher serum insulin and apoB concentrations,
and female kidney recipients also more weight than the
same patients after cessation of prednisone [8]. Accord-
ing to Ekstrand [7], the most important mechanism asso-
ciated with steroid-induced insulin resistance is decreased
activity of glycogen synthase. This, together with de-
creased insulin secretion, predisposes to glucose intoler-
ance [7]. Glucocorticoids might increase lipid production
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and impair lipid catabolism in the liver [8, 31]. In our
study, both kidney and liver recipients were on similar
low-dose, every-other-day corticosteroid regimens, the
average dosage being slightly higher in kidney than in
liver recipients. Although no dose-dependent influence
was seen, the features of insulin resistance found in both
of our Tx groups could have been due to corticosteroid
therapy.
Small, dense LDL is associated with increased risk
of coronary heart disease [14]. Hypertriglyceridemia, in-
sulin resistance, and hypertension have been reported to
be associated with increased prevalence of small, dense
LDL [33]. Our kidney recipients especially had risk fac-
tors for increased prevalence of small, dense LDL. Thus,
it was unexpected that neither small, dense LDL nor LDL
prone to in vitro oxidative modification existed more fre-
quently in our patients than controls. In fact, kidney recip-
ients seemed to have rather increased frequency of large
LDL diameters. The rare occurrence of small, dense LDL
in our patients may be explained by age, as full penetra-
tion has been reported in only subjects over 20 years of
age or genetic predisposition to larger-sized LDL [16].
Nevertheless, small, dense LDL was rare in our patients.
We wanted to model these lipoproteins in order to see
whether the risk factors usually reported to influence the
prevalence of small, dense LDL controlled the variation
of LDL diameters in our patients. In our KTx patients,
LDL diameter showed an independent positive associa-
tion with HDL-C, and an inverse univariate association
with TG concentration, as previously reported in adults
with or without Tx [14, 34]. In previous reports, TG con-
centration has typically been the strongest determinant
of LDL diameter, but in our study HDL-C concentra-
tion was the most important univariate lipid determinant,
explaining up to 40.7% of variation of LDL diameter
in our kidney patients. Due to the metabolic relation-
ship between a high TG and a low HDL-C concentration
(increased catabolic rate of triglyceride-rich HDL par-
ticles resulting in low HDL-C concentration) [35], the
association of LDL diameter with HDL-C concentra-
tion probably reflected some persisting influence of the
hypertriglyceridemia. Our kidney recipients had higher
concentrations of HDL-C and apoA-I than our controls,
probably because glucocorticoid therapy increases HDL-
C concentration and apoA-I messenger RNA levels [36],
and reduces plasma cholesterol ester transfer protein ac-
tivity [8]. This might indicate efficient reverse cholesterol
transport, which supports the catabolism of triglyceride-
rich lipoproteins decreasing the formation of small, dense
LDL [37, 38]. Contrary to our initial hypothesis and a pre-
vious report on Japanese children [39], insulin resistance,
seen especially in our patients with ongoing puberty, and
obesity were not associated with small, dense, but rather
with large LDL diameters in our patients. Thus, in pedi-
atric kidney or liver recipients, the cardiovascular risk did
not seem to be mediated through small, dense, and easily
oxidative LDL.
According to the 6-day food records, the amount of fat
in the diet (percent of energy) did not differ statistically
significantly between the groups, but high relative carbo-
hydrate intake was more common in liver than in kid-
ney patients. Previously, high carbohydrate diet has been
shown to be associated with increased concentration of
TG and prevalence of small, dense LDL [40]. These as-
sociations of high carbohydrate diet were not seen in our
patients, probably due to the complex influence of diet
on lipoprotein values, and also due to the multifarious
nature of dyslipidemia in solid organ recipients.
Previously, in kidney transplant patients receiving
CsA, a shorter lag time for LDL oxidation has been seen
[34, 41, 42]. In our patients, we saw no pro-oxidant effect
of CsA. Our patients used CsA in microemulsion com-
position containing DL-alpha tocopherol, which might
act as an antioxidative agent [43]. Still, in vitro studies
do not suggest CsA to be a direct pro-oxidant [44]. In
vivo, HDL protects LDL against lipid peroxidation via
various mechanisms, as acting as a reservoir for lipid per-
oxides and retarding LDL oxidation by HDL-associated
enzymes [18]. Our kidney and liver patients and controls
were different in associations of cholesterol with lag time.
However, patients with GH treatment had a longer lag
time in both Tx groups. These findings remain to be ex-
plained. With regard to lipid metabolism, kidney and liver
are metabolically different organs because the liver plays
an essential, well-known role in the synthesis and storage
of lipids, while deteriorating kidney function leads to al-
terations in concentrations and compositions of lipids, but
the role of kidney in the regulation of lipid homeostasis
is not clearly known.
In our study, multivariate associations were assessed
first in blocks that let us include more independent vari-
ables in analysis (Table 1). We tried to group possible
related risk factors in a block (e.g., kidney and liver func-
tion). However, in the block of patient characteristics, the
variables were only weakly related. This setting did not
allow all interactions between the variables to be studied,
and the final model may not show the best possible subset
of all variables in first blocks.
CONCLUSION
Higher TG and insulin concentrations were found in
kidney and liver transplant recipients compared to con-
trols. Also, features of dysmetabolic syndrome, except in-
creased prevalence of small, dense, and easily oxidative
LDL, were seen in both organ recipient groups. HDL-
C concentration was the most important determinant for
LDL particle size in all groups. These preliminary findings
in a limited number of pediatric kidney and liver recip-
ients should be followed up with a larger patient group
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in the future. Because dyslipidemia, hypertension, dys-
metabolic syndrome, and new-onset insulin-dependent
diabetes are risk factors for future cardiovascular disease,
the occurrence of these risk factors should be minimized,
and be a prime consideration in any management strategy
to reduce the mortality and morbidity of cardiovascular
diseases in pediatric transplant recipients.
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